Dr. Wang received his MD from the Harvard-MIT Health Sciences and Technology Program at Harvard Medical School. He then obtained his clinical training from the Harvard Radiation Oncology Program. Dr. Wang also completed a postdoctoral research fellowship at MIT under the mentorship of Dr. Robert Langer. Following training, Dr. Wang first joined the faculty at University of North Carolina Chapel Hill in 2009. He then joined UTSW in 2021 is currently the A. Kenneth Pye Professor in Cancer Research and Vice Chair of Clinical and Translational research. As a physician scientist, Dr. Wang’s research program is focused on the clinical translation of engineering sciences, including Nanomedicine, to oncology. His research spans a wide spectrum of translational research, from preclinical research to early phase clinical trials. His research has been supported by grants from the NIH/NCI, Department of Defense, foundations and industry. Dr. Wang has received numerous awards such as Fellow of American Institute for Medical and the American Society for Clinical Investigation. He has cofounded 2 biotech startup companies. He is CEO and cofounder of Capio Biosciences, a startup translating a highly sensitive circulating tumor cell capture technology. He recently cofounded Archimmune Therapeutics, a startup developing nanotechnology-based cancer immunotherapies. He is on the editorial Boards of Journal of the National Cancer Institute, Nanomedicine NBM and WIRES Nano.
Andrew Zhuang Wang, MD